Preclinical development of molecular-targeted agents for cancer
作者： Alberto Ocana , Atanasio Pandiella , Lillian L. Siu , Ian F. Tannock
DOI: 10.1038/NRCLINONC.2010.194
关键词:
摘要: Molecular-targeted agents are increasingly used for the treatment of cancer. However, attrition rate drugs that enter early clinical trials is higher than other branches internal medicine, suggesting preclinical development has not been successful in identifying can modify outcome human New strategies including genetically engineered mouse models and small-interfering RNAs being to evaluate novel agents, have aided compounds, such as inhibitors phosphatidylinositol 3-kinase or poly(ADP-ribose) polymerase. In addition, these techniques helped identification promising combinations targeted drugs. this Review, we describe methods evaluation their limitations, improvement.
nature.com
sci-hub.se 参考文章(119)
Michael W.N. Deininger, John M. Goldman, Nicholas Lydon, Junia V. Melo, The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells Blood. ,vol. 90, pp. 3691- 3698 ,(1997) , 10.1182/BLOOD.V90.9.3691
M.C. Bibby, Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages European Journal of Cancer. ,vol. 40, pp. 852- 857 ,(2004) , 10.1016/J.EJCA.2003.11.021
Brian J. Druker, Conor Heaney, James D. Griffin, John R. Hagopian, Keiko Okuda, Tsukasa Oda, Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. Journal of Biological Chemistry. ,vol. 269, pp. 22925- 22928 ,(1994) , 10.1016/S0021-9258(17)31596-X
Nicholas Turner, Andrew Tutt, Alan Ashworth, Hallmarks of 'BRCAness' in sporadic cancers Nature Reviews Cancer. ,vol. 4, pp. 814- 819 ,(2004) , 10.1038/NRC1457
Noah Craft, Yuriy Shostak, Michael Carey, Charles L. Sawyers, A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine. ,vol. 5, pp. 280- 285 ,(1999) , 10.1038/6495
Dieter Marmé, Joachim Drevs, Harald Hugenschmidt, Clemens Unger, Jeanette Wood, Georg Martiny-Baron, Helmut Madjar, Christine Wittig, Marianne Müller, Inga Hofmann, Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model Cancer Research. ,vol. 60, pp. 4819- 4824 ,(2000)
Ismail Kola, John Landis, Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery. ,vol. 3, pp. 711- 716 ,(2004) , 10.1038/NRD1470
J. Dirk Iglehart, Daniel P. Silver, Synthetic Lethality — A New Direction in Cancer-Drug Development New England Journal of Medicine. ,vol. 361, pp. 189- 191 ,(2009) , 10.1056/NEJME0903044
Alberto Ocaña, Gabriel N. Hortobagyi, Francisco J. Esteva, Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer Clinical Breast Cancer. ,vol. 6, pp. 495- 504 ,(2006) , 10.3816/CBC.2006.N.002
Ralph Weissleder, Scaling down imaging: molecular mapping of cancer in mice Nature Reviews Cancer. ,vol. 2, pp. 11- 18 ,(2002) , 10.1038/NRC701